280 related articles for article (PubMed ID: 32485363)
21. Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1.
Chery J; Petri A; Wagschal A; Lim SY; Cunningham J; Vasudevan S; Kauppinen S; Näär AM
Nucleic Acid Ther; 2018 Oct; 28(5):273-284. PubMed ID: 30133337
[TBL] [Abstract][Full Text] [Related]
22. The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery.
Gagliardi M; Ashizawa AT
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33923688
[TBL] [Abstract][Full Text] [Related]
23. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
24. Fibrin-hyaluronic acid hydrogel-based delivery of antisense oligonucleotides for ADAMTS5 inhibition in co-delivered and resident joint cells in osteoarthritis.
Garcia JP; Stein J; Cai Y; Riemers F; Wexselblatt E; Wengel J; Tryfonidou M; Yayon A; Howard KA; Creemers LB
J Control Release; 2019 Jan; 294():247-258. PubMed ID: 30572032
[TBL] [Abstract][Full Text] [Related]
25. Antisense technology: an overview and prospectus.
Crooke ST; Baker BF; Crooke RM; Liang XH
Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737
[TBL] [Abstract][Full Text] [Related]
26. Cerebral Organoids and Antisense Oligonucleotide Therapeutics: Challenges and Opportunities.
Lange J; Zhou H; McTague A
Front Mol Neurosci; 2022; 15():941528. PubMed ID: 35836547
[TBL] [Abstract][Full Text] [Related]
27. Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm.
Grabowska-Pyrzewicz W; Want A; Leszek J; Wojda U
EBioMedicine; 2021 Dec; 74():103691. PubMed ID: 34773891
[TBL] [Abstract][Full Text] [Related]
28. Delivery of mutant huntingtin-lowering antisense oligonucleotides to the brain by intranasally administered apolipoprotein A-I nanodisks.
Aly AE; Caron NS; Black HF; Schmidt ME; Anderson C; Ko S; Baddeley HJE; Anderson L; Casal LL; Rahavi RSM; Martin DDO; Hayden MR
J Control Release; 2023 Aug; 360():913-927. PubMed ID: 37468110
[TBL] [Abstract][Full Text] [Related]
29. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
[TBL] [Abstract][Full Text] [Related]
30. Antisense Oligonucleotide-Based Therapy of Viral Infections.
Tarn WY; Cheng Y; Ko SH; Huang LM
Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959297
[TBL] [Abstract][Full Text] [Related]
31. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
32. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.
Swayze EE; Siwkowski AM; Wancewicz EV; Migawa MT; Wyrzykiewicz TK; Hung G; Monia BP; Bennett CF
Nucleic Acids Res; 2007; 35(2):687-700. PubMed ID: 17182632
[TBL] [Abstract][Full Text] [Related]
33. Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.
Chen S; Heendeniya SN; Le BT; Rahimizadeh K; Rabiee N; Zahra QUA; Veedu RN
BioDrugs; 2024 Mar; 38(2):177-203. PubMed ID: 38252341
[TBL] [Abstract][Full Text] [Related]
34. Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases.
Schoch KM; Miller TM
Neuron; 2017 Jun; 94(6):1056-1070. PubMed ID: 28641106
[TBL] [Abstract][Full Text] [Related]
35. Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides.
Uemura Y; Kobayashi K
Drug Deliv; 2019 Dec; 26(1):803-811. PubMed ID: 31385541
[TBL] [Abstract][Full Text] [Related]
36. Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding.
Kusznir EA; Hau JC; Portmann M; Reinhart AG; Falivene F; Bastien J; Worm J; Ross A; Lauer M; Ringler P; Sladojevich F; Huber S; Bleicher K; Keller M
Bioconjug Chem; 2023 May; 34(5):866-879. PubMed ID: 37145959
[TBL] [Abstract][Full Text] [Related]
37. Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models.
Kim Y; Jo M; Schmidt J; Luo X; Prakash TP; Zhou T; Klein S; Xiao X; Post N; Yin Z; MacLeod AR
Mol Ther; 2019 Sep; 27(9):1547-1557. PubMed ID: 31303442
[TBL] [Abstract][Full Text] [Related]
38. Antisense oligonucleotides: a promising therapeutic option against infectious diseases.
Tekintaş Y; Temel A
Nucleosides Nucleotides Nucleic Acids; 2024; 43(1):1-39. PubMed ID: 37395450
[TBL] [Abstract][Full Text] [Related]
39. Medicinal Chemistry of Antisense Oligonucleotides for Therapeutic Use in SARS-CoV-2: Design Strategies and Challenges for Targeted Delivery.
Nedaeinia R; Ranjbar M; Goli M; Etebari M; Safabakhsh S; Bayram H; Ferns GA; Tehrani HM; Salehi R
Curr Med Chem; 2024 Jun; ():. PubMed ID: 38860908
[TBL] [Abstract][Full Text] [Related]
40. Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.
Karaosmanoglu B; Imren G; Utine E; Taylan Sekeroglu H; Taskiran EZ
Exp Eye Res; 2024 Apr; 241():109833. PubMed ID: 38369231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
